Assessing Heart Failure Patients - Where Does CCM® Therapy Fit

February 3, 2021

Heart Failure is a progressive condition and medical management strategies for this patient population has evolved over the years. Assessment of Heart Failure utilizing the NYHA Heart Failure Classification System and EF have been used to diagnose patients and assist providers with optimizing medications and device therapy. This program will discuss the fundamental elements to assessing your heart failure patient classification and to stratify them for therapy that it is available for them. The program will introduce CCM® therapy as an option for patients that have NYHA Stage III heart failure and remain symptomatic despite guideline medical therapy. The Optimizer® was designed to improve overall heart function and quality of life for patients. CCM® indications will be discussed as well as best practices for screening patients for HCPs to offer this therapy for patients that qualify for this technology.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login